Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $49.81 million. The enterprise value is $117.91 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Celularity has 23.95 million shares outstanding. The number of shares has increased by 22.89% in one year.
Current Share Class | 23.95M |
Shares Outstanding | 23.95M |
Shares Change (YoY) | +22.89% |
Shares Change (QoQ) | +1.44% |
Owned by Insiders (%) | 13.53% |
Owned by Institutions (%) | 14.67% |
Float | 11.68M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.84 |
Forward PS | n/a |
PB Ratio | 5.31 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 2.17 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.38, with a Debt / Equity ratio of 7.79.
Current Ratio | 0.38 |
Quick Ratio | 0.27 |
Debt / Equity | 7.79 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -6.15 |
Financial Efficiency
Return on equity (ROE) is -232.51% and return on invested capital (ROIC) is -26.18%.
Return on Equity (ROE) | -232.51% |
Return on Assets (ROA) | -17.42% |
Return on Invested Capital (ROIC) | -26.18% |
Return on Capital Employed (ROCE) | -48.80% |
Revenue Per Employee | $440,813 |
Profits Per Employee | -$470,667 |
Employee Count | 123 |
Asset Turnover | 0.39 |
Inventory Turnover | 2.69 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.92% in the last 52 weeks. The beta is 0.76, so Celularity's price volatility has been lower than the market average.
Beta (5Y) | 0.76 |
52-Week Price Change | -36.92% |
50-Day Moving Average | 1.81 |
200-Day Moving Average | 2.18 |
Relative Strength Index (RSI) | 51.66 |
Average Volume (20 Days) | 111,400 |
Short Selling Information
The latest short interest is 1.61 million, so 6.70% of the outstanding shares have been sold short.
Short Interest | 1.61M |
Short Previous Month | 1.68M |
Short % of Shares Out | 6.70% |
Short % of Float | 13.74% |
Short Ratio (days to cover) | 22.42 |
Income Statement
In the last 12 months, Celularity had revenue of $54.22 million and -$57.89 million in losses. Loss per share was -$2.64.
Revenue | 54.22M |
Gross Profit | 39.23M |
Operating Income | -38.55M |
Pretax Income | -196.29M |
Net Income | -57.89M |
EBITDA | -30.63M |
EBIT | -38.55M |
Loss Per Share | -$2.64 |
Full Income Statement Balance Sheet
The company has $738,000 in cash and $68.84 million in debt, giving a net cash position of -$68.10 million or -$2.84 per share.
Cash & Cash Equivalents | 738,000 |
Total Debt | 68.84M |
Net Cash | -68.10M |
Net Cash Per Share | -$2.84 |
Equity (Book Value) | 8.84M |
Book Value Per Share | 0.39 |
Working Capital | -33.12M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$6.40 million and capital expenditures -$161,000, giving a free cash flow of -$6.56 million.
Operating Cash Flow | -6.40M |
Capital Expenditures | -161,000 |
Free Cash Flow | -6.56M |
FCF Per Share | -$0.27 |
Full Cash Flow Statement Margins
Gross margin is 72.36%, with operating and profit margins of -71.10% and -106.77%.
Gross Margin | 72.36% |
Operating Margin | -71.10% |
Pretax Margin | -106.77% |
Profit Margin | -106.77% |
EBITDA Margin | -56.49% |
EBIT Margin | -71.10% |
FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.89% |
Shareholder Yield | -22.89% |
Earnings Yield | -116.22% |
FCF Yield | -13.17% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Feb 29, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Celularity has an Altman Z-Score of -10 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10 |
Piotroski F-Score | 4 |